
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1015 | 970 | 1057 | 1061 | 1597 | 2486 |
Fund Return | 1.51% | -2.99% | 5.69% | 1.98% | 9.81% | 9.53% |
Place in category | 47 | 8 | 271 | 361 | 224 | 161 |
% in Category | 11 | 3 | 56 | 78 | 55 | 45 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Artisan International Value Instl | 22.6B | 6.17 | 10.21 | 7.91 | ||
Artisan International Value Advisor | 11.12B | 6.13 | 10.11 | - | ||
Artisan Mid Cap Advisor | 4.01B | 1.47 | 1.88 | - | ||
Artisan Mid Cap Investor | 4.01B | 1.47 | 1.76 | 9.28 | ||
Artisan International Small Cap Ins | 3.11B | 1.49 | -0.40 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Principal MidCap Institutional | 14.6B | 3.95 | 11.91 | 12.12 | ||
Vanguard Mid-Cap Growth Index Admir | 12.89B | 2.32 | 6.64 | 10.11 | ||
T. Rowe Price Mid-Cap Growth I | 11.91B | -1.57 | 4.66 | - | ||
T. Rowe Price Mid-Cap Growth | 10.95B | -1.59 | 4.52 | 9.48 | ||
T. Rowe Price New Horizons I | 8.55B | -2.44 | -2.12 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
argenx ADR | US04016X1019 | 4.97 | 605.52 | -0.40% | |
Spotify Tech | LU1778762911 | 4.20 | 615.88 | +1.85% | |
West Pharmaceutical Services | US9553061055 | 3.84 | 225.80 | -2.63% | |
Tyler Technologies | US9022521051 | 3.64 | 580.30 | +1.03% | |
Ascendis Pharma AS | US04351P1012 | 3.22 | 161.04 | -4.14% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Sell | Strong Sell |
Technical Indicators | BUY | Strong Sell | Sell |
Summary | Neutral | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review